The World Bank Yemen Schistosomiasis (P113102) REPORT NO.: RES29461 DOCUMENT OF THE WORLD BANK RESTRUCTURING PAPER ON A PROPOSED PROJECT RESTRUCTURING OF YEMEN SCHISTOSOMIASIS APPROVED ON DECEMBER 17, 2009 TO MINISTRY OF PLANNING AND INTERNATIONAL COOPERATION HEALTH, NUTRITION & POPULATION MIDDLE EAST AND NORTH AFRICA Regional Vice President: Hafez M. H. Ghanem Country Director: Asad Alam Senior Global Practice Director: Timothy Grant Evans Practice Manager/Manager: Ernest E. Massiah Task Team Leader: Moustafa Mohamed ElSayed Mohamed Abdalla The World Bank Yemen Schistosomiasis (P113102) I. BASIC DATA Product Information Project ID Financing Instrument P113102 Specific Investment Loan Original EA Category Current EA Category Not Required (C) Not Required (C) Approval Date Current Closing Date 17-Dec-2009 30-Sep-2017 Organizations Borrower Responsible Agency Ministry of Planning and International Cooperation Ministry of Public Health & Population Project Development Objective (PDO) Original PDO The project objective is to decrease the prevalence and intensity of infection of both urinary and intestinal Schistosomiasis among school-aged children by 2015 in endemic regions in Yemen. Summary Status of Financing Net Ln/Cr/Tf Approval Signing Effectiveness Closing Commitment Disbursed Undisbursed IDA-H5420 17-Dec-2009 06-Jan-2010 03-Aug-2010 30-Sep-2017 25.00 22.40 1.09 Policy Waiver(s) Does this restructuring trigger the need for any policy waiver(s)? No II. SUMMARY OF PROJECT STATUS AND PROPOSED CHANGES The World Bank Yemen Schistosomiasis (P113102) The approved partial lifting of suspension of disbursements for the Schistosomiasis Project on December 21, 2015 allowed: (i) the execution of new Operational and Technical agreements with WHO to procure and distribute essential drugs through their existing local delivery networks on the ground; and (ii) direct payments for the technical and financial independent verification, and to pay for external auditing services. Since the signing of the agreement between the Project Administration Unit and WHO, all the funding of the new agreement along with the existing ones have been disbursed. WHO has completed almost all planned activities and submitted the purchase orders for the required remaining Praziquantel in late March 2017. To date, the Project has disbursed 95 percent of the total project funding and successfully completed the two planned school-aged children (SAC) campaigns in 2017, which treated 2.1 million children 6-18 years old with around 4.6 million tablets of Praziquantel. These SAC campaigns were conducted in 31 districts across 14 governorates with a particular focus on the high prevalence areas. Many indicators have achieved or surpassed the target. For example, prevalence of infection has come down to 6.9 percent (target: 10 percent) as well as the prevalence of heavy or medium infection of intestinal schistosomiasis at 1.0 percent (target: 2.5 percent). The Project has reached 92 percent of enrolled children (target: 80 percent) and 79 percent of non-enrolled children (target: 70 percent). This translates to covering 88 percent of enrolled and non- enrolled SAC compared to 75 percent target. The Project will need to be extended for 4 months to allow for the completion of the Praziquantel procurement. Most of the human resources and logistical capacities of the Yemen WHO Country Office and of the Djibouti hub have been mobilized for the cholera outbreak response, resulting in the delay in completing the Praziquantel procurement. III. DETAILED CHANGES LOAN CLOSING DATE(S) Original Revised Proposed Proposed Deadline Ln/Cr/Tf Status Closing Closing(s) Closing for Withdrawal Applications 30-Jun-2017, 30-Sep- IDA-H5420 Effective 30-Jun-2016 31-Jan-2018 31-May-2018 2017